A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Cannot have received:

Treatment-naive B-cell malignancies

Cannot have received: autologous stem cell transplant

Exception: allowed if > 3 months prior to screening

Autologous stem cell transplant ≤ 3 months prior to screening

Cannot have received: CAR-T cell therapy

Exception: allowed if > 3 months prior to screening

chimeric antigen T-cell therapy ≤ 3 months prior to screening

Cannot have received: allogeneic stem cell transplant

Exception: Substudies 1 and 2: excluded if active GVHD, requiring immunosuppressive drugs for GVHD, or calcineurin inhibitors within 4 weeks prior to consent; Substudies 3 and 4: all prior allogeneic stem cell transplant excluded

Substudies 1 and 2: Prior allogeneic stem cell transplant with active graft-versus-host disease (GVHD), or requiring immunosuppressive drugs for treatment of GVHD, or who have taken calcineurin inhibitors within 4 weeks prior to consent; Substudies 3 and 4: All participants with a prior allogeneic stem cell transplant

Cannot have received: BCL2 inhibitor

Exception: Substudy 1: allowed if relapsed ≥ 24 months after completion of a full course of a prior Bcl-2 inhibitor containing regimen

Substudy 1: Prior treatment with a B-cell lymphoma-2 (Bcl-2) inhibitor (with exception for participants who relapsed ≥ 24 months after completion of a full course of a prior Bcl-2 inhibitor containing regimen)

Cannot have received: (zanubrutinib)

Exception: Substudy 2: excluded only if discontinued due to intolerance

Substudy 2: Participants who discontinued prior zanubrutinib treatment due to intolerance

Cannot have received: CD20 x CD3 T-cell engager antibody

Substudies 3 and 4: Prior exposure to a CD20 x CD3 T-cell engager antibody treatment